Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of nine innovative product candidates. Millennium's website is




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:8/1/2014)... LAWRENCE, Mass. , Aug. 1, 2014  NxStage Medical, ... innovative dialysis products, today announced that Jeffrey H. Burbank ... Financial Officer, will present at the 34 th Annual ... Boston, MA , on Wednesday, August 13 ... event will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
(Date:7/31/2014)... , July 31, 2014  According to data ... Services, the 2015 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... GeneXpert(R) System ... ... today announced the U.S. Food & Drug Administration (FDA) categorized,Cepheid,s ... Clinical Laboratory Improvement Amendments (CLIA).,The new test is designed for ...
... Michael J. Fox,Foundation today announced the availability of ... toward transformative treatments and a cure for,Parkinson,s disease., ... researchers through the,Foundation,s Pipeline Programs, five separate initiatives ... drug development pipeline. This includes,early-stage discovery research, translational ...
Cached Medicine Technology:Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 4Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 2Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 3Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 4
(Date:8/1/2014)... NJ (PRWEB) August 01, 2014 ... web portal that aims to empower patients and ... in their health care by providing easy, secure ... Portal gives patients instant, web-based access to their ... and radiology results, medications, allergies, demographic information, visit ...
(Date:8/1/2014)... procedures have grown in popularity as more and more ... toxin generally known as BOTOX use ... have emerged to perform procedures utilizing this and other ... from the Division of Plastic Surgery Presbyterian Hospital in ... University in New York have assessed the capability of ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 St. Christopher's ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , St. Christopher's Hospital ... services for children from birth through 21 years of ... several of the hospital's specialties, including autism and childhood ...
(Date:8/1/2014)... Narconon Arrowhead recently celebrated the occasion ... drug rehab center located in the small town of ... is the flagship drug rehab center in the Narconon ... for services there. Now, with such a long track ... as well as client reviews showing the effectiveness of ...
(Date:8/1/2014)... TX (PRWEB) August 01, 2014 Delta ... the Year for its outstanding commitment to St. Jude ... the hospital since 1999 and pledging to raise another ... combat childhood cancer and other deadly diseases. , ... any single partner in St. Jude history. Specifically, it ...
Breaking Medicine News(10 mins):Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 2Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 3
... that vitamin C was vital for good health and could ... ,Dr Margret Vissers, from Otago University's Free Radical Research ... vitamin C was a vital part of healthy living and ... had a cold. ,"I've found that vitamin C ...
... nerve cells in the brain and lead to depression, according to ... and Science in North Chicago. ,The team led by Daniel ... rats for 20 minutes. The older rats quickly cornered, pinned down ... ,The younger rats became fearful and acted depressed in the ...
... below seven is fast depleting, which has sent the Ministry of ... Company CSL had stopped the production of the Tet-tox vaccine in ... is just enough to last till the end of this month. ... drugs will have to be used by those who are in ...
... New research suggests that a child’s race may ... tobacco toxins associated with environmental tobacco smoke (ETS). ... asthma, who are exposed to ETS, have significantly ... counterparts. ,“African American children suffer from ...
... question of bloodshot eyes anymore. After sleepless nights, a person’s ... has been found//. ,Sleep deprivation lowers metabolic ... colleagues at Walter Reed Army Institute of Research, report in ... group of volunteers to two sleepless nights, they found that ...
... Patients can start using their mobile phones when the ban ... in the hospitals because it was believed// that its electromagnetic ... per the directive issued from the Department of Health, cell ... equipments. ,This announcement has brought in cheer ...
Cached Medicine News:Health News:Vitamin C Could Help in Curbing Cancer 2Health News:Race Affects Tobacco Absorption in Children 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: